PAR DRUGS Q2 : STANDALONE NET PROFIT DOWN 36.4% AT ₹2.63 CR (YOY), DOWN 44.2% (QOQ). WEAK (ON 1ST LOOK)

Revenue down 4.3% at ₹27.43 Cr (YoY), down 12.3% (QoQ). EBITDA at ₹4.50 Cr; margins 16.4% v 22.8% (YoY), 23.4% (QoQ). PBT down 36.2% at ₹3.54 Cr (YoY), down 44.0% (QoQ); EPS ₹2.14 v ₹3.36 (YoY).

Par Drugs and Chemicals Limited

Open attachment

← Back to feed